Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease.
Identifieur interne : 002D17 ( PubMed/Curation ); précédent : 002D16; suivant : 002D18Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease.
Auteurs : Thanh G. Ton [États-Unis] ; Susan R. Heckbert ; W T Longstreth ; Mary Anne Rossing ; Walter A. Kukull ; Gary M. Franklin ; Phillip D. Swanson ; Terri Smith-Weller ; Harvey CheckowaySource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal (administration & dosage), Aspirin (administration & dosage), Case-Control Studies, Cross-Sectional Studies, Female, Humans, Ibuprofen (administration & dosage), Male, Middle Aged, Odds Ratio, Oxidative Stress (drug effects), Parkinson Disease (diagnosis), Parkinson Disease (epidemiology), Parkinson Disease (prevention & control), Retrospective Studies, Risk, Washington.
- MESH :
- chemical , administration & dosage : Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Ibuprofen.
- geographic : Washington.
- diagnosis : Parkinson Disease.
- drug effects : Oxidative Stress.
- epidemiology : Parkinson Disease.
- prevention & control : Parkinson Disease.
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Odds Ratio, Retrospective Studies, Risk.
Abstract
Inflammation and oxidative stress have been implicated as pathogenic mechanisms in Parkinson's disease (PD). Evidence from in vitro and animal studies suggests a possible protective role of nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin. We investigated the risk of PD associated with use of aspirin and nonaspirin NSAIDs in a population-based case-control study among enrollees of Group Health Cooperative, a health maintenance organization in the Seattle area. Subjects included 206 cases between ages 35 and 89 with a new diagnosis of idiopathic PD between 1992 and 2002, and 383 randomly selected controls frequency-matched by age, sex, duration of enrollment, and clinic. We obtained information on participants' age, smoking, and medical history from interview. Exposure to NSAIDs was ascertained from an automated pharmacy database. Medications filled within 5 years of the interview were excluded. After adjusting for age, sex, smoking, duration of enrollment, and clinic, the risk of PD among individuals who received nonaspirin NSAIDs between 1977 and 1992 was 0.90 (95% CI: 0.59-1.35) and 1.67 (95% CI: 0.60-4.60) between 1993 and 2002. Use of ibuprofen was not associated with PD (OR: 0.89; 95% CI: 0.60-1.32). The risk of PD associated with aspirin or aspirin-containing medications was 0.74 (95% CI: 0.49-1.12). We observed no trend in risk according to number of fills for these drugs. Our results provide only limited support for the hypothesis that use of aspirin may reduce the risk of this disease, and no indication of protection from other NSAIDs.
DOI: 10.1002/mds.20856
PubMed: 16550541
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002D17
Links to Exploration step
pubmed:16550541Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease.</title><author><name sortKey="Ton, Thanh G" sort="Ton, Thanh G" uniqKey="Ton T" first="Thanh G" last="Ton">Thanh G. Ton</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, University of Washington, Seattle, Washington 98195, USA. thanhton@u.washington.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington 98195</wicri:regionArea></affiliation></author><author><name sortKey="Heckbert, Susan R" sort="Heckbert, Susan R" uniqKey="Heckbert S" first="Susan R" last="Heckbert">Susan R. Heckbert</name></author><author><name sortKey="Longstreth, W T" sort="Longstreth, W T" uniqKey="Longstreth W" first="W T" last="Longstreth">W T Longstreth</name></author><author><name sortKey="Rossing, Mary Anne" sort="Rossing, Mary Anne" uniqKey="Rossing M" first="Mary Anne" last="Rossing">Mary Anne Rossing</name></author><author><name sortKey="Kukull, Walter A" sort="Kukull, Walter A" uniqKey="Kukull W" first="Walter A" last="Kukull">Walter A. Kukull</name></author><author><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M" last="Franklin">Gary M. Franklin</name></author><author><name sortKey="Swanson, Phillip D" sort="Swanson, Phillip D" uniqKey="Swanson P" first="Phillip D" last="Swanson">Phillip D. Swanson</name></author><author><name sortKey="Smith Weller, Terri" sort="Smith Weller, Terri" uniqKey="Smith Weller T" first="Terri" last="Smith-Weller">Terri Smith-Weller</name></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.20856</idno><idno type="RBID">pubmed:16550541</idno><idno type="pmid">16550541</idno><idno type="wicri:Area/PubMed/Corpus">002D17</idno><idno type="wicri:Area/PubMed/Curation">002D17</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease.</title><author><name sortKey="Ton, Thanh G" sort="Ton, Thanh G" uniqKey="Ton T" first="Thanh G" last="Ton">Thanh G. Ton</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, University of Washington, Seattle, Washington 98195, USA. thanhton@u.washington.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of Washington, Seattle, Washington 98195</wicri:regionArea></affiliation></author><author><name sortKey="Heckbert, Susan R" sort="Heckbert, Susan R" uniqKey="Heckbert S" first="Susan R" last="Heckbert">Susan R. Heckbert</name></author><author><name sortKey="Longstreth, W T" sort="Longstreth, W T" uniqKey="Longstreth W" first="W T" last="Longstreth">W T Longstreth</name></author><author><name sortKey="Rossing, Mary Anne" sort="Rossing, Mary Anne" uniqKey="Rossing M" first="Mary Anne" last="Rossing">Mary Anne Rossing</name></author><author><name sortKey="Kukull, Walter A" sort="Kukull, Walter A" uniqKey="Kukull W" first="Walter A" last="Kukull">Walter A. Kukull</name></author><author><name sortKey="Franklin, Gary M" sort="Franklin, Gary M" uniqKey="Franklin G" first="Gary M" last="Franklin">Gary M. Franklin</name></author><author><name sortKey="Swanson, Phillip D" sort="Swanson, Phillip D" uniqKey="Swanson P" first="Phillip D" last="Swanson">Phillip D. Swanson</name></author><author><name sortKey="Smith Weller, Terri" sort="Smith Weller, Terri" uniqKey="Smith Weller T" first="Terri" last="Smith-Weller">Terri Smith-Weller</name></author><author><name sortKey="Checkoway, Harvey" sort="Checkoway, Harvey" uniqKey="Checkoway H" first="Harvey" last="Checkoway">Harvey Checkoway</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)</term><term>Aspirin (administration & dosage)</term><term>Case-Control Studies</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Ibuprofen (administration & dosage)</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Oxidative Stress (drug effects)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson Disease (prevention & control)</term><term>Retrospective Studies</term><term>Risk</term><term>Washington</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Aspirin</term><term>Ibuprofen</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Washington</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Oxidative Stress</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Retrospective Studies</term><term>Risk</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Inflammation and oxidative stress have been implicated as pathogenic mechanisms in Parkinson's disease (PD). Evidence from in vitro and animal studies suggests a possible protective role of nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin. We investigated the risk of PD associated with use of aspirin and nonaspirin NSAIDs in a population-based case-control study among enrollees of Group Health Cooperative, a health maintenance organization in the Seattle area. Subjects included 206 cases between ages 35 and 89 with a new diagnosis of idiopathic PD between 1992 and 2002, and 383 randomly selected controls frequency-matched by age, sex, duration of enrollment, and clinic. We obtained information on participants' age, smoking, and medical history from interview. Exposure to NSAIDs was ascertained from an automated pharmacy database. Medications filled within 5 years of the interview were excluded. After adjusting for age, sex, smoking, duration of enrollment, and clinic, the risk of PD among individuals who received nonaspirin NSAIDs between 1977 and 1992 was 0.90 (95% CI: 0.59-1.35) and 1.67 (95% CI: 0.60-4.60) between 1993 and 2002. Use of ibuprofen was not associated with PD (OR: 0.89; 95% CI: 0.60-1.32). The risk of PD associated with aspirin or aspirin-containing medications was 0.74 (95% CI: 0.49-1.12). We observed no trend in risk according to number of fills for these drugs. Our results provide only limited support for the hypothesis that use of aspirin may reduce the risk of this disease, and no indication of protection from other NSAIDs.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16550541</PMID><DateCreated><Year>2006</Year><Month>08</Month><Day>28</Day></DateCreated><DateCompleted><Year>2006</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>7</Issue><PubDate><Year>2006</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>964-9</MedlinePgn></Pagination><Abstract><AbstractText>Inflammation and oxidative stress have been implicated as pathogenic mechanisms in Parkinson's disease (PD). Evidence from in vitro and animal studies suggests a possible protective role of nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin. We investigated the risk of PD associated with use of aspirin and nonaspirin NSAIDs in a population-based case-control study among enrollees of Group Health Cooperative, a health maintenance organization in the Seattle area. Subjects included 206 cases between ages 35 and 89 with a new diagnosis of idiopathic PD between 1992 and 2002, and 383 randomly selected controls frequency-matched by age, sex, duration of enrollment, and clinic. We obtained information on participants' age, smoking, and medical history from interview. Exposure to NSAIDs was ascertained from an automated pharmacy database. Medications filled within 5 years of the interview were excluded. After adjusting for age, sex, smoking, duration of enrollment, and clinic, the risk of PD among individuals who received nonaspirin NSAIDs between 1977 and 1992 was 0.90 (95% CI: 0.59-1.35) and 1.67 (95% CI: 0.60-4.60) between 1993 and 2002. Use of ibuprofen was not associated with PD (OR: 0.89; 95% CI: 0.60-1.32). The risk of PD associated with aspirin or aspirin-containing medications was 0.74 (95% CI: 0.49-1.12). We observed no trend in risk according to number of fills for these drugs. Our results provide only limited support for the hypothesis that use of aspirin may reduce the risk of this disease, and no indication of protection from other NSAIDs.</AbstractText><CopyrightInformation>(c) 2006 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ton</LastName><ForeName>Thanh G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle, Washington 98195, USA. thanhton@u.washington.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heckbert</LastName><ForeName>Susan R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Longstreth</LastName><ForeName>W T</ForeName><Initials>WT</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Rossing</LastName><ForeName>Mary Anne</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Franklin</LastName><ForeName>Gary M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Swanson</LastName><ForeName>Phillip D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Smith-Weller</LastName><ForeName>Terri</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Checkoway</LastName><ForeName>Harvey</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ES04696</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ES07033</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ES10750</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 ES007262</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>WK2XYI10QM</RegistryNumber><NameOfSubstance UI="D007052">Ibuprofen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001241">Aspirin</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003430">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007052">Ibuprofen</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016017">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012306">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014861">Washington</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20856</ArticleId><ArticleId IdType="pubmed">16550541</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D17 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002D17 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16550541
|texte= Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16550541" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |